Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 September 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 189 pages)

 

Export 11 results:
Author [ Title(Desc)] Type Year
Filters: Author is Donegan, K.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
K. Donegan, Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., and Bryan, P., “Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK”, Vaccine, vol. 31, pp. 4961-7, 2013.
E
G. Amirthalingam, Andrews, N., Campbell, H., Ribeiro, S., Kara, E., Donegan, K., Fry, N. K., Miller, E., and Ramsay, M., “Effectiveness of maternal pertussis vaccination in England: an observational study”, Lancet, vol. 384, pp. 1521-8, 2014.
K. Hedenmalm, Blake, K., Donegan, K., Macia, M. A., Gil, M., Williams, J., Montero, D., Candore, G., Morales, D., Kurz, X., and Arlett, P., “A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children”, Pharmacoepidemiol Drug Saf, 2019.
J. Wong, Donegan, K., Seabroke, S., and Bryan, P., “Evaluation of compliance to the timing of childhood vaccinations following introduction of the meningococcal B vaccine in the UK”, Drug Safety, vol. 40, pp. 1000-1, 2017.
K. Donegan, Owen, R., Bird, H., Burch, B., Smith, A., and Tregunno, P., “Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study”, Drug Saf, vol. 41, pp. 899-910, 2018.
H
R. E. Ghosh, Crellin, E., Beatty, S., Donegan, K., Myles, P., and Williams, R., “How Clinical Practice Research Datalink data are used to support pharmacovigilance”, Therapeutic Advances in Drug Safety, 2019.
I
C. Allen and Donegan, K., “The impact of regulatory action on the co-prescribing of renin-angiotensin system blockers in UK primary care”, Pharmacoepidemiol Drug Saf, vol. 26, pp. 858-862, 2017.
P
P. Datta-Nemdharry, Thomson, A., Beynon, J., and Donegan, K., “Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales”, Pharmacoepidemiol Drug Saf, vol. 26, pp. 127-135, 2017.
S
P. Bryan, Seabroke, S., Wong, J., Donegan, K., Webb, E., Goldsmith, C., Vipond, C., and Feavers, I., “Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study”, Lancet Child Adolesc Health, vol. 2, pp. 395-403, 2018.
K. Donegan, King, B., and Bryan, P., “Safety of pertussis vaccination in pregnant women in UK: observational study”, Bmj, vol. 349, p. g4219, 2014.
T
K. Donegan, Fox, N., Black, N., Livingston, G., Banerjee, S., and Burns, A., “Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study”, Lancet Public Health, vol. 2, pp. e149-e156, 2017.
[Page last reviewed 6 September 2019]